Commission Must Change Course on Reusable Packaging Demands – EPPA
17.11.2022 07:00:00 EET | Business Wire | Press release
As the EU prepares to set strict new targets on packaging waste, a mounting body of evidence shows that proposed targets on reusables are unscientific, unsustainable and unnecessary.
The European Paper Packaging Alliance (EPPA) has issued fresh calls for the European Commission to put the full product life cycle at the heart of its vision for a circular economy, and not to use the upcoming Packaging and Packaging Waste Regulation proposal to effectively outlaw packaging solutions that are more sustainable.
The latest evidence comes from a new life cycle analysis study, which shows that recyclable, paper-based packaging used in the food delivery and takeaway sector offers significant environmental advantages over reusable systems across 12 ‘impact categories’ including climate change, freshwater consumption and resource depletion.
The results show that switching to reusable alternatives would generate 48% more CO2-equivalent emissions, consume 39% more freshwater and demand 82% more mineral and resource extraction.
Analysis of the results shows that this is because transporting food and beverage containers back to restaurants after use, together with washing and drying them hygienically, consumes far more energy, water and resources.
This LCA study adds to a range of other evidence which shows that reusable container systems are not the panacea which some seem to believe.
Commenting on the findings, Eric Le Lay, President of the European Paper Packaging Alliance said:
“ This is more proof that reusable packaging is not always the best solution for the environment. It is imperative that proper life cycle analysis be reflected in the text of the EU’s Packaging and Packaging Waste Regulation proposal.
The leaked draft text of the regulation is disappointing. It sets unrealistic and discriminatory reuse targets for in-store dining and takeaway services. The European Commission should embrace the scientific evidence that single-use, paper-based containers are not only far more practical for food delivery services and their customers, improving hygiene and convenience, but simply perform better on key environmental metrics.”
Antonio D’Amato, Vice President of EPPA, also commented:
“ Protecting the planet is too important a priority to be left to ideology. The planet's health demands a rigorous scientific approach and substantial investment in new technology and innovation, which can only be generated by sustainable growth.
Europe and indeed the entire world face energy and water scarcity and food shortages, yet the Commission's current proposals would escalate carbon emissions and resource depletion, accelerate water stress and increase food waste. We should instead be working together on solutions that are truly sustainable for the environment, the economy and employment. We are convinced that the circular economy, in which we have all invested billions of euros over 30 years’ hard work and innovation, is the only way to provide sustainable solutions for the environment, economy and employment. ”
The study was commissioned by EPPA. The full study including its methodology description is available for download here.
About EPPA:
The European Paper Packaging Alliance is a non-for-profit food and foodservice packaging association. The priorities of the Alliance are to find concrete solutions to increase recycling and to reduce carbon emissions of food and foodservice packaging without compromising food safety and human health protection. More information is available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005869/en/
Contact information
Roxana Moldovan
+32 485955210
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
